Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017

被引：15
|
作者：
Frank I. Scott
Gary R. Lichtenstein
机构：
[1] University of Colorado Anschutz Medical Campus,Crohn’s and Colitis Center, Division of Gastroenterology and Hepatology
[2] Perelman School of Medicine,Gastroenterology Division
[3] University of Pennsylvania,undefined
来源：
Current Treatment Options in Gastroenterology | 2018年 / 16卷 / 1期
关键词：
Biosimilars; Indication extrapolation; Interchangeability; Infliximab; Adalimumab; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis;
D O I：
10.1007/s11938-018-0177-z
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：147 / 164
页数：17
相关论文
共 50 条
  • [21] Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease
    Raffals, Laura E.
    Nguyen, Geoffrey C.
    Rubin, David T.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (05) : 818 - 823
  • [22] Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease
    Macaluso, Fabio Salvatore
    Leone, Salvatore
    Previtali, Enrica
    Ventimiglia, Marco
    Armuzzi, Alessandro
    Orlando, Ambrogio
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (11) : 1304 - 1309
  • [23] Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
    Ben-Horin, Shomron
    Vande Casteele, Niels
    Schreiber, Stefan
    Lakatos, Peter Laszlo
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (12) : 1685 - 1696
  • [24] The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease
    Patil, Seema A.
    Bhat, Shubha
    Limdi, Jimmy K.
    Farraye, Francis A.
    Cross, Raymond K.
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (12) : 1915 - 1923
  • [25] Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo, Marjorie
    Fiorino, Gionata
    Gilardi, Daniela
    Furfaro, Federica
    Roda, Giulia
    Loy, Laura
    Allocca, Mariangela
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (01) : 7 - 12
  • [26] Biosimilars in inflammatory bowel disease: ready for prime time?
    Gomollon, Fernando
    CURRENT OPINION IN GASTROENTEROLOGY, 2015, 31 (04) : 290 - 295
  • [27] The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease
    Severs, M.
    Oldenburg, B.
    van Bodegraven, A. A.
    Siersema, P. D.
    Mangen, M-J. J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (03): : 289 - 296
  • [28] Position statement on the use of biosimilars in inflammatory bowel disease
    Emanuel, Burri
    Pascal, Juillerat
    Michel, Maillard H.
    Michael, Manz
    Pierre, Michetti
    Christian, Mottet
    Gerhard, Rogler
    Nadine, Zahnd
    Stephan, Vavricka
    SWISS MEDICAL WEEKLY, 2019, 149
  • [29] Current status of biosimilars in the treatment of inflammatory bowel diseases
    Park, Dong Il
    INTESTINAL RESEARCH, 2016, 14 (01) : 15 - 20
  • [30] Preliminary Evidence Supporting a Framework of Psychological Adjustment to Inflammatory Bowel Disease
    Kiebles, Jennifer L.
    Doerfler, Bethany
    Keefer, Laurie
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (10) : 1685 - 1695
12345